Evidence map›Paper›PMID 40060127›Full record

ArticleArchives of rheumatology2024

Pediatric to adult rheumatology transition: Success rates, influencing factors, and evolving diagnoses and treatments.

Tuba Demirci Yıldırım, Rana İşgüder, Ezgi Karaçura, Yeşim Erez, Balahan Makay, Fatoş Önen, Şevket Erbil Ünsal, İsmail Sarı

Abstract read
In one paragraph

Article in Archives of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tuba Demirci YıldırımDepartment of Internal Medicine, Division of Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0003-3186-0591
Rana İşgüderDepartment of Pediatrics, Division of Pediatric Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-6070-8196
Ezgi KaraçuraDepartment of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0001-5449-6660
Yeşim ErezDepartment of Internal Medicine, Division of Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-2669-2880
Balahan MakayDepartment of Pediatrics, Division of Pediatric Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0001-6193-0402
Fatoş ÖnenDepartment of Internal Medicine, Division of Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-6341-2622
Şevket Erbil ÜnsalDepartment of Pediatrics, Division of Pediatric Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-8800-0800
İsmail SarıDepartment of Internal Medicine, Division of Rheumatology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0001-7737-4180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to evaluate the rate of successful transitions, identify factors associated with early versus late transitions, and diagnosis and treatment changes after transition into adult rheumatology. Patients and methods: In this retrospective study, patients with childhood-onset rheumatic diseases who transitioned from pediatric to adult rheumatology care between January 2013 and January 2023 were screened for a successful transition. Successful transitions were defined as maintaining annual visits to the adult rheumatology clinic after transition. Early transition was defined as less than three months between the last pediatric and first adult rheumatology visits. Results: Out of 2,552 referred patients, 210 (8.2%) patients (117 females, 93 males; mean age: 25.2±5.6 years; range, 18 to 44 years) transitioned successfully. Juvenile idiopathic arthritis and familial Mediterranean fever were the most prevalent rheumatic diseases. The median transition time was four months (interquartile range, 1 to 13 months) in patients with successful transition, and the early transition rate was 46.7%. Receiving biologic disease-modifying antirheumatic drugs was found to be associated with early transition (28.6% Conclusion: A successful transition to adult rheumatology is essential for adolescents and young adults with childhood-onset rheumatic diseases. The successful transition rate in this study was relatively low, highlighting the need for standardized transition programs.

Indexed as

Disease-modifying antirheumatic drugsjuvenile idiopathic arthritispediatric rheumatologytransition.

Identifiers

PMID40060127
PMCPMC11883249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.